CD80 and neoplasm: Indeed, by inhibiting CTLA-4 in 19z1-CD80+ T cells in which the CD28 signal comes from endogenous CD28 receptors activated by CD80 ligation, we almost reached the anti-tumor capacity of 19-28z+ T cells, in which CD28 costimulation is provided trough the CAR.